Dyadic’s CHO-alternative, the C1 production platform, could reduce time and cost at almost every stage of the cell development and biomanufacturing process, says CEO.
Sartorius will invest around 10% of its annual revenues into its manufacturing network to support continued double-digit growth of its bioprocessing equipment business.
